

Croyez's GFP LNP-mRNA is specifically optimized for high-efficiency delivery into hard-to-transfect immune cells such as Jurkat. The formulation utilizes sequence-optimized mRNA, advanced ionizable lipid chemistry, and functional validation to ensure robust expression with minimal cytotoxicity for both *in vitro* and *in vivo* applications.

HEK 293 T cells




Figure 1. HEK 293 T cells (0.5 x 10⁵ cells per well, 24-well plate) were transfected with 100 ng of GFP LNP-mRNA.

Feature

- Efficient Delivery
- Minimal Toxicity
- Superior Expression
- Broad Versatility

Jurkat cells





Figure 2. Jurkat cells (2x10⁵ cells per well, 24-well plate) were transfected with 100 ng of GFP LNP-mRNA.



Cell Transfection Efficiency

GFP mRNA enables quick assessment of delivery efficiency within hours, while monitoring fluorescence and cell viability..




mRNA Carrier & Delivery Validation

Evaluate LNP or lipid carriers for packaging, release, and tissue-specific uptake to confirm successful delivery.



Gene Expression Studies

Analyze how 5' Cap, 3' poly(A), or UTR designs affect mRNA stability, expression levels, and translation efficiency.



Live-Cell Imaging & Tracking

Use GFP labeling and live-cell microscopy to trace cell migration and monitor targeted populations over time.

services

Croyez provides mRNA synthesis materials and services, covering mRNA reporter genes and mRNA CRISPR-Cas9. The company is also actively developing sa-mRNA (self-amplifying mRNA) to enhance the stability and expression efficiency of vaccine development, protein replacement therapy, and gene editing.

